Abstract | Background: Methods: Patients received oral vorinostat (300 or 400 mg/day) on days 1-5 weekly during temozolomide chemoradiation. Following a 4- to 6-week rest, patients received up to 12 cycles of standard adjuvant temozolomide and vorinostat (400 mg/day) on days 1-7 and 15-21 of each 28-day cycle. Association between vorinostat response signatures and progression-free survival (PFS) and overall survival (OS) was assessed based on RNA sequencing of baseline tumor tissue. Results: Phase I and phase II enrolled 15 and 107 patients, respectively. The combination therapy MTD was vorinostat 300 mg/day and temozolomide 75 mg/m2/day. Dose-limiting toxicities were grade 4 neutropenia and thrombocytopenia and grade 3 aspartate aminotransferase elevation, hyperglycemia, fatigue, and wound dehiscence. The primary efficacy endpoint in the phase II cohort, OS rate at 15 months, was 55.1% (median OS 16.1 mo), and consequently, the study did not meet its efficacy objective. Most common treatment-related grade 3/4 toxicities in the phase II component were lymphopenia (32.7%), thrombocytopenia (28.0%), and neutropenia (21.5%). RNA expression profiling of baseline tumors (N = 76) demonstrated that vorinostat resistance (sig-79) and sensitivity (sig-139) signatures had a reverse and positive association with OS/PFS, respectively. Conclusions:
Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma. Although the primary efficacy endpoint was not met, vorinostat sensitivity and resistance signatures could facilitate patient selection in future trials.
|
Authors | Evanthia Galanis, S Keith Anderson, C Ryan Miller, Jann N Sarkaria, Kurt Jaeckle, Jan C Buckner, Keith L Ligon, Karla V Ballman, Dennis F Moore Jr, Michael Nebozhyn, Andrey Loboda, David Schiff, Manmeet Singh Ahluwalia, Eudocia Q Lee, Elizabeth R Gerstner, Glenn J Lesser, Michael Prados, Stuart A Grossman, Jane Cerhan, Caterina Giannini, Patrick Y Wen, Alliance for Clinical Trials in Oncology and ABTC |
Journal | Neuro-oncology
(Neuro Oncol)
Vol. 20
Issue 4
Pg. 546-556
(03 27 2018)
ISSN: 1523-5866 [Electronic] England |
PMID | 29016887
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Brain Neoplasms
(pathology, therapy)
- Chemoradiotherapy
- Cohort Studies
- Female
- Follow-Up Studies
- Glioblastoma
(pathology, therapy)
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Prognosis
- Survival Rate
- Temozolomide
(administration & dosage)
- Vorinostat
(administration & dosage)
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|